Antimicrobial Resistance: Is the World UNprepared?
Long Blurb:
On September 21st 2016 the United Nations General Assembly convenes in New York, United States to tackle a looming and seemingly inevitable global challenge with the potential to threaten the health and wellbeing of all people: antimicrobial resistance. In an Editorial, the PLOS Medicine Editors reflect on the challenge of coordinating the response to antimicrobial resistance in order to ensure the viability of current antimicrobials and the development of new therapies against resistant pathogens. Short Blurb: In this month's Editorial, the PLOS Medicine Editors reflect on the upcoming United Nations General Assembly meeting which convenes to discuss the global challenge of antimicrobial resistance.
Vyšlo v časopise:
Antimicrobial Resistance: Is the World UNprepared?. PLoS Med 13(9): e32767. doi:10.1371/journal.pmed.1002130
Kategorie:
Editorial
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1002130
Souhrn
Long Blurb:
On September 21st 2016 the United Nations General Assembly convenes in New York, United States to tackle a looming and seemingly inevitable global challenge with the potential to threaten the health and wellbeing of all people: antimicrobial resistance. In an Editorial, the PLOS Medicine Editors reflect on the challenge of coordinating the response to antimicrobial resistance in order to ensure the viability of current antimicrobials and the development of new therapies against resistant pathogens. Short Blurb: In this month's Editorial, the PLOS Medicine Editors reflect on the upcoming United Nations General Assembly meeting which convenes to discuss the global challenge of antimicrobial resistance.
Zdroje
1. United Nations. High-level Meeting on Antimicrobial Resistance. http://www.un.org/pga/70/events/high-level-meeting-on-antimicrobial-resistance/ Accessed 16 August 2016.
2. Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen J-A, Klugman K, Davies S (2016). Access to effective antimicrobials: a worldwide challenge. The Lancet, Volume 387, Issue 10014, 168–175. http://dx.doi.org/10.1016/S0140-6736(15)00474-2
3. Liu LI, Shefali O, Hogan D, Perin J, Rudan I, Lawn JE et al (2015). Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. The Lancet. Volume 385, Issue 9966, 430–440. http://dx.doi.org/10.1016/S0140-6736(14)61698-6
4. The Review on Antimicrobial Resistance, chaired by Jim O’Neill. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. Dec 2014. http://www.jpiamr.eu/wp-content/uploads/2014/12/AMR-Review-Paper-Tackling-a-crisis-for-the-health-and-wealth-of-nations_1-2.pdf
5. Laxminarayan R, Chaudhury RR (2016). Antibiotic Resistance in India: Drivers and Opportunities for Action. PLoS Med 13(3): e1001974. doi: 10.1371/journal.pmed.1001974 26934098
6. Laxminarayan R, Amábile-Cuevas CF, Cars O, Evans T, Heymann DL, Hoffman S et al (2016). UN High-Level Meeting on antimicrobials—what do we need? The Lancet, Volume 388, Issue 10041, 218–220 http://dx.doi.org/10.1016/S0140-6736(16)31079-0
7. Laxminarayan R, Sridhar D, Blaser M, Wang M, Woolhouse M. (2016). Achieving global targets for antimicrobial resistance. Science. doi: 10.1126/science.aaf9286
8. Sun LH. Major global partnership to speed antibiotic development launched. The Washington Post. 28 July 2016. https://www.washingtonpost.com/news/to-your-health/wp/2016/07/28/major-global-partnership-to-speed-antibiotic-development-launched/
9. WHO. Global action plan on antimicrobial resistance. http://www.who.int/drugresistance/global_action_plan/en/ Accessed 16 August 2016
10. Outterson K, Gopinathan U, Clift C, So AD, Morel CM, Røttingen J-A (2016). Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality. PLoS Med 13(6): e1002043. doi: 10.1371/journal.pmed.1002043 27299990
11. Balasegaram M, Bréchot C, Farrar J, Heymann D, Ganguly N, Khor M, et al (2015). A Global Biomedical R&D Fund and Mechanism for Innovations of Public Health Importance. PLoS Med 12(5): e1001831. doi: 10.1371/journal.pmed.1001831 25962119
12. DNDi. Global Antibiotic Research & Development (GARD). Partnership. http://www.dndi.org/diseases-projects/gard/ Accessed 16 August 2016 doi: 10.1021/acs.jmedchem.5b01699 26901446
13. Årdal C, Outterson K, Hoffman SJ, Ghafur A, Sharland M, Ranganathan N, et al. (2015) International cooperation to improve access to and sustain effectiveness of antimicrobials. The Lancet, Volume 387, Issue 10015, 296–307 http://dx.doi.org/10.1016/S0140-6736(15)00470-5
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2016 Číslo 9
- Statiny indukovaná myopatie: Jak na diferenciální diagnostiku?
- MUDr. Dana Vondráčková: Hepatopatie sú pri liečbe metamizolom väčším strašiakom ako agranulocytóza
- Vztah mezi statiny a rizikem vzniku nádorových onemocnění − metaanalýza
- Nech brouka žít… Ať žije astma!
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
Najčítanejšie v tomto čísle
- Sex Differences in Tuberculosis Burden and Notifications in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis
- International Criteria for Acute Kidney Injury: Advantages and Remaining Challenges
- Potential for Controlling Cholera Using a Ring Vaccination Strategy: Re-analysis of Data from a Cluster-Randomized Clinical Trial
- Tenofovir Pre-exposure Prophylaxis for Pregnant and Breastfeeding Women at Risk of HIV Infection: The Time is Now